{
    "clinical_study": {
        "@rank": "1552", 
        "arm_group": {
            "arm_group_label": "Alogliptin/pioglitazone (Liovel) combination tablets", 
            "description": "Alogliptin/pioglitazone (Liovel) combination tablets, taken orally, once daily for up to 12 months"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the safety and efficacy of long-term use of\n      alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes\n      mellitus determined as warranting  combination therapy with alogliptin benzoate and\n      pioglitazone hydrochloride"
        }, 
        "brief_title": "Alogliptin/Pioglitazone (Liovel) Liovel Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a special drug use surveillance on long-term use of alogliptin/pioglitazone\n      combination tablets.  This study is designed to investigate the safety and efficacy of\n      long-term use of alogliptin/pioglitazone combination tablet in patients with type 2 diabetes\n      mellitus in the routine clinical setting.\n\n      Participants will be patients with type 2 diabetes mellitus. The planned sample size is\n      3000.\n\n      The usual adult dosage is 1 tablet (containing alogliptin/pioglitazone at either 25 mg/15 mg\n      or 25 mg/30 mg) taken orally once daily before or after breakfast."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with type 2 diabetes mellitus\n\n        Exclusion Criteria:\n\n          -  Patients meeting any of the following criteria will be excluded:\n\n               1. Patients with current cardiac failure or a past history of cardiac failure\n\n               2. Patients with severe ketosis, diabetic coma or precoma, or type 1 diabetes\n                  mellitus\n\n               3. Patients with serious hepatic dysfunction\n\n               4. Patients with serious renal dysfunction\n\n               5. Patients with severe infection, pre- or post-operative patients, or patients\n                  with serious traumatic injury\n\n               6. Patients with a history of hypersensitivity to any ingredients of Liovel\n\n               7. Pregnant or possibly pregnant women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with type 2 diabetes mellitus who have been examined at a medical institution"
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01990300", 
            "org_study_id": "136-011", 
            "secondary_id": "JapicCTI-132302"
        }, 
        "intervention": {
            "arm_group_label": "Alogliptin/pioglitazone (Liovel) combination tablets", 
            "description": "Alogliptin/pioglitazone combination tablets", 
            "intervention_name": "Alogliptin/pioglitazone", 
            "intervention_type": "Drug", 
            "other_name": "Liovel\u3001SYR-322-4833"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pioglitazone", 
                "Alogliptin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug Therapy", 
        "lastchanged_date": "November 15, 2013", 
        "number_of_groups": "1", 
        "official_title": "Long-term Use of Alogliptin/Pioglitazone Combination Tablets in Patients With Type 2 Diabetes Mellitus", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The frequency of adverse events by type, seriousness, type to onset, etc. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.", 
                "measure": "Frequency of Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at month 12 relative to baseline.", 
                "measure": "Change from Baseline in Glycosylated Hemoglobin (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and month 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01990300"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change in the value of fasting blood glucose collected at month 12 relative to baseline.", 
            "measure": "Change from Baselin in Fasting blood glucose", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 12 months"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}